J.J.T.M. Heuvel

1.1k total citations
22 papers, 886 citations indexed

About

J.J.T.M. Heuvel is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, J.J.T.M. Heuvel has authored 22 papers receiving a total of 886 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cancer Research, 9 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in J.J.T.M. Heuvel's work include Protease and Inhibitor Mechanisms (11 papers), Cell Adhesion Molecules Research (8 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). J.J.T.M. Heuvel is often cited by papers focused on Protease and Inhibitor Mechanisms (11 papers), Cell Adhesion Molecules Research (8 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). J.J.T.M. Heuvel collaborates with scholars based in Netherlands, Denmark and United States. J.J.T.M. Heuvel's co-authors include Fred C.G.J. Sweep, L.V.A.M. Beex, Paul N. Span, John A. Foekens, Peggy Manders, T J Benraad, Anneke Geurts‐Moespot, J Witte, Nils Brünner and Remko R. Bosch and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and British Journal of Cancer.

In The Last Decade

J.J.T.M. Heuvel

22 papers receiving 855 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.J.T.M. Heuvel Netherlands	16	444	401	399	142	112	22	886
Ann Thor United States	9	311 0.7×	409 1.0×	293 0.7×	79 0.6×	78 0.7×	9	750
Susan Burdette-Radoux United States	12	212 0.5×	461 1.1×	470 1.2×	115 0.8×	134 1.2×	26	1.2k
K Hibi Japan	9	310 0.7×	492 1.2×	590 1.5×	38 0.3×	54 0.5×	18	1.1k
Kimberley Howarth United Kingdom	15	384 0.9×	347 0.9×	631 1.6×	272 1.9×	138 1.2×	20	1.4k
Lisa M. Bafetti United States	8	348 0.8×	234 0.6×	325 0.8×	235 1.7×	104 0.9×	10	674
Paolo Squicciarini Italy	11	549 1.2×	453 1.1×	215 0.5×	82 0.6×	23 0.2×	15	918
Yvonne T.M. Tsang United States	18	211 0.5×	329 0.8×	533 1.3×	137 1.0×	27 0.2×	24	1.2k
Ulrike Lacher Germany	10	284 0.6×	295 0.7×	631 1.6×	43 0.3×	31 0.3×	14	942
A. Reza Radjabi United States	8	569 1.3×	287 0.7×	793 2.0×	101 0.7×	40 0.4×	9	1.3k
Christina V. Obiezu Canada	14	122 0.3×	285 0.7×	303 0.8×	151 1.1×	320 2.9×	16	1.0k

Countries citing papers authored by J.J.T.M. Heuvel

Since Specialization

Citations

This map shows the geographic impact of J.J.T.M. Heuvel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.J.T.M. Heuvel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.J.T.M. Heuvel more than expected).

Fields of papers citing papers by J.J.T.M. Heuvel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.J.T.M. Heuvel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.J.T.M. Heuvel. The network helps show where J.J.T.M. Heuvel may publish in the future.

Co-authorship network of co-authors of J.J.T.M. Heuvel

This figure shows the co-authorship network connecting the top 25 collaborators of J.J.T.M. Heuvel. A scholar is included among the top collaborators of J.J.T.M. Heuvel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.J.T.M. Heuvel. J.J.T.M. Heuvel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bussink, Johan, Blanca Scheijen, Irıs D. Nagtegaal, et al.. (2011). Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Research. 13(4). R82–R82. 73 indexed citations

Span, Paul N., Anieta M. Sieuwerts, J.J.T.M. Heuvel, et al.. (2008). Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: An EU-FP6 supported study of members of the EORTC – PathoBiology Group. European Journal of Cancer. 45(1). 74–81. 2 indexed citations

Span, Paul N., Vivianne C. G. Tjan‐Heijnen, J.J.T.M. Heuvel, et al.. (2006). Do the Survivin (BIRC5) Splice Variants Modulate or Add to the Prognostic Value of Total Survivin in Breast Cancer?. Clinical Chemistry. 52(9). 1693–1700. 47 indexed citations

Span, Paul N., Raija L.P. Lindberg, Peggy Manders, et al.. (2004). Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP‐3 is associated with adjuvant endocrine therapy success. The Journal of Pathology. 202(4). 395–402. 48 indexed citations

Span, Paul N., Esmé Waanders, Peggy Manders, et al.. (2004). Mammaglobin Is Associated With Low-Grade, Steroid Receptor-Positive Breast Tumors From Postmenopausal Patients, and Has Independent Prognostic Value for Relapse-Free Survival Time. Journal of Clinical Oncology. 22(4). 691–698. 65 indexed citations

Span, Paul N., Peggy Manders, J.J.T.M. Heuvel, L.V.A.M. Beex, & Fred C.G.J. Sweep. (2003). E1AF Expression Levels are not Associated with Prognosis in Human Breast Cancer. Breast Cancer Research and Treatment. 79(1). 129–131. 7 indexed citations

Span, Paul N., Peggy Manders, J.J.T.M. Heuvel, et al.. (2003). Molecular Beacon Reverse Transcription-PCR of Human Chorionic Gonadotropin-β-3, -5, and -8 mRNAs Has Prognostic Value in Breast Cancer. Clinical Chemistry. 49(7). 1074–1080. 20 indexed citations

Span, Paul N., Peggy Manders, J.J.T.M. Heuvel, et al.. (2002). Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene. 21(55). 8506–8509. 111 indexed citations

Witte, J, John A. Foekens, Nils Brünner, et al.. (2001). Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. British Journal of Cancer. 85(1). 85–92. 38 indexed citations

10.

Span, Paul N., J.J.T.M. Heuvel, S Romain, et al.. (2000). EORTC receptor and biomarker study group report analytical and technical evaluation of a thymidine kinase radio-enzymatic assay in breast cancer cytosols.. PubMed. 20(2A). 681–7. 5 indexed citations

11.

Sweep, Fred C.G.J., et al.. (1999). ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA?PAI-1 and tPA?PAI-1). International Journal of Cancer. 81(4). 598–606. 21 indexed citations

12.

Sweep, Fred C.G.J., et al.. (1999). ELISA for complexes of urokinase‐type and tissue‐type plasminogen activators with their type‐1 inhibitor (uPA∼PAI‐1 and tPA∼PAI‐1). International Journal of Cancer. 81(4). 598–606. 1 indexed citations

13.

Witte, J, Fred C.G.J. Sweep, J.G.M. Klijn, et al.. (1999). Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. British Journal of Cancer. 79(7-8). 1190–1198. 38 indexed citations

14.

Witte, J, Fred C.G.J. Sweep, J.G.M. Klijn, et al.. (1999). Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. British Journal of Cancer. 80(1-2). 286–294. 37 indexed citations

15.

Sweep, Fred C.G.J., J Geurts-Moespot, J Witte, et al.. (1998). External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. British Journal of Cancer. 78(11). 1434–1441. 97 indexed citations

16.

Sweep, Fred C.G.J., et al.. (1998). Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. International Journal of Cancer. 77(2). 236–242. 29 indexed citations

17.

Geurts‐Moespot, Anneke, et al.. (1997). A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols. The International Journal of Biological Markers. 12(1). 6–14. 80 indexed citations

18.

Benraad, Th. J., J Geurts-Moespot, J Grøndahl-Hansen, et al.. (1996). Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop. European Journal of Cancer. 32(8). 1371–1381. 57 indexed citations

19.

Koenders, P., et al.. (1991). Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers.. PubMed. 51(17). 4544–8. 72 indexed citations

20.

Heuvel, J.J.T.M., et al.. (1991). Six methods for direct radioiodination of mouse epidermal growth factor compared: effect of nonequivalence in binding behavior between labeled and unlabeled ligand.. PubMed. 37(10 Pt 1). 1749–55. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact